<p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）于周四发布了其财报。公司报告本季度每股收益（EPS）为（$1.69），低于市场共识预期的（$1.33），差距为（$0.36），Briefing.com 报道称。在去年同期，公司每股收益为（$0.81）。</p>
<p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<h2>Vera Therapeutics 股票表现</h2>
<ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>周四午盘交易中，纳斯达克代码：VERA 的股票下跌 $0.72，报 $35.88。该公司的交易量为 972,545 股，而其平均交易量为 1,190,760 股。公司的 50 日移动平均价格为 $39.96，200 日移动平均价格为 $40.35。公司的流动比率为 13.64，速动比率为 13.64，债务股本比率为 0.12。该股票的市值为 25.6 亿美元，市盈率为 -7.70，贝塔值为 0.96。Vera Therapeutics 的 52 周低点为 $18.76，52 周高点为 $56.05。</p>
<h2>分析师评级上调与下调</h2>
<p>几家研究机构最近对 VERA 发布了报告。HC Wainwright 将 Vera Therapeutics 的目标价格从 $90.00 上调至 $110.00，并在 3 月 2 日的研究报告中给予该股票 “买入” 评级。Wolfe Research 将 Vera Therapeutics 的评级从 “同行表现” 上调至 “跑赢大盘”，并在 3 月 11 日的报告中设定了 $88.00 的目标价格。最后，Weiss Ratings 在 4 月 20 日的报告中重新发布了对 Vera Therapeutics 的 “卖出（d-）” 评级。十位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 $79.60。</p>
<p><strong>查看我们关于 VERA 的最新研究报告</strong></p>
<h2>内部人士买卖情况</h2>
<p>在相关消息中，首席运营官 David Lee Johnson 于 2 月 23 日星期一出售了 2,579 股公司的股票。股票以平均价格 $41.98 出售，总价值为 $108,266.42。交易后，首席运营官直接持有 45,727 股公司的股票，价值约为 $1,919,619.46。此次交易使其持股减少了 5.34%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，高级副总裁 Joseph R. Young 于 2 月 23 日星期一出售了 3,117 股公司的股票。股票以平均价格 $41.98 出售，总交易额为 $130,851.66。出售后，高级副总裁直接持有 64,722 股公司的股票，价值约为 $2,717,029.56。此次交易使其持股减少了 4.59%。该出售的 SEC 备案提供了更多信息。在过去九十天内，内部人士出售了价值 $2,416,902 的 56,441 股公司股票。公司内部人士持有 15.90% 的公司股票。</p>
<h2>机构投资者对 Vera Therapeutics 的看法</h2>
<p>几家机构投资者最近增加或减少了对 VERA 的持股。洛杉矶资本管理公司在第四季度购买了价值约 $46,000 的 Vera Therapeutics 新股份。Quantbot Technologies LP 在第二季度购买了价值约 $51,000 的 Vera Therapeutics 新股份。Aster Capital Management DIFC Ltd 在第四季度购买了价值约 $71,000 的 Vera Therapeutics 新股份。Tower Research Capital LLC TRC 在第二季度将其在 Vera Therapeutics 的持股增加了 192.9%。Tower Research Capital LLC TRC 现在拥有 4,186 股公司的股票，价值 $99,000，此前在该期间又购买了 2,757 股。最后，Sandia Investment Management LP 在第四季度购买了价值约 $127,000 的 Vera Therapeutics 新股份。99.21% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Vera Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用身体自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、改变疾病进程的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
<p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥，与领先的学术和研究机构合作，推动其开发项目。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Vera Therapeutics 吗？</h2>
<p>在考虑投资 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERA

标普生物技术 3 倍做空 - Direxion

IBBQ

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

<p>Vera Therapeutics（纳斯达克代码：VERA）报告的季度每股收益为（$1.69），低于市场共识预期的（$1.33），差距为（$0.36）。这比去年同期的每股收益（$0.81）有所下降。该股交易下跌至$35.88，市值为$25.6 亿。分析师的评级意见不一，市场共识评级为 “适度买入”，平均目标价为$79.60。近期注意到内部人士的股票出售和机构投资，企业内部人士持有该股票的 15.90%</p>

<p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) posted its earnings results on Thursday. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36), Briefing.com reports. During the same period in the previous year, the company posted ($0.81) EPS.</p>
<div class="lb-trans"><p>Vera Therapeutics（纳斯达克代码：VERA - 获取免费报告）于周四发布了其财报。公司报告本季度每股收益（EPS）为（$1.69），低于市场共识预期的（$1.33），差距为（$0.36），Briefing.com 报道称。在去年同期，公司每股收益为（$0.81）。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><h2>Vera Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票表现</h2>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Shares of NASDAQ:VERA traded down $0.72 during midday trading on Thursday, reaching $35.88. The company had a trading volume of 972,545 shares, compared to its average volume of 1,190,760. The company's 50 day moving average price is $39.96 and its 200 day moving average price is $40.35. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. The stock has a market cap of $2.56 billion, a P/E ratio of -7.70 and a beta of 0.96. Vera Therapeutics has a 52-week low of $18.76 and a 52-week high of $56.05.</p>
<div class="lb-trans"><p>周四午盘交易中，纳斯达克代码：VERA 的股票下跌 $0.72，报 $35.88。该公司的交易量为 972,545 股，而其平均交易量为 1,190,760 股。公司的 50 日移动平均价格为 $39.96，200 日移动平均价格为 $40.35。公司的流动比率为 13.64，速动比率为 13.64，债务股本比率为 0.12。该股票的市值为 25.6 亿美元，市盈率为 -7.70，贝塔值为 0.96。Vera Therapeutics 的 52 周低点为 $18.76，52 周高点为 $56.05。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several research firms have recently issued reports on VERA. HC Wainwright upped their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, March 2nd. Wolfe Research raised shares of Vera Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $88.00 price target on the stock in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $79.60.</p>
<div class="lb-trans"><p>几家研究机构最近对 VERA 发布了报告。HC Wainwright 将 Vera Therapeutics 的目标价格从 $90.00 上调至 $110.00，并在 3 月 2 日的研究报告中给予该股票 “买入” 评级。Wolfe Research 将 Vera Therapeutics 的评级从 “同行表现” 上调至 “跑赢大盘”，并在 3 月 11 日的报告中设定了 $88.00 的目标价格。最后，Weiss Ratings 在 4 月 20 日的报告中重新发布了对 Vera Therapeutics 的 “卖出（d-）” 评级。十位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 $79.60。</p>
</div><p><strong>Check Out Our Latest Research Report on VERA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 VERA 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In related news, COO David Lee Johnson sold 2,579 shares of the business's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the transaction, the chief operating officer directly owned 45,727 shares of the company's stock, valued at approximately $1,919,619.46. The trade was a 5.34% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 3,117 shares of the company's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $130,851.66. Following the sale, the senior vice president directly owned 64,722 shares in the company, valued at approximately $2,717,029.56. This trade represents a 4.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 56,441 shares of company stock worth $2,416,902 in the last ninety days. Corporate insiders own 15.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席运营官 David Lee Johnson 于 2 月 23 日星期一出售了 2,579 股公司的股票。股票以平均价格 $41.98 出售，总价值为 $108,266.42。交易后，首席运营官直接持有 45,727 股公司的股票，价值约为 $1,919,619.46。此次交易使其持股减少了 5.34%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，高级副总裁 Joseph R. Young 于 2 月 23 日星期一出售了 3,117 股公司的股票。股票以平均价格 $41.98 出售，总交易额为 $130,851.66。出售后，高级副总裁直接持有 64,722 股公司的股票，价值约为 $2,717,029.56。此次交易使其持股减少了 4.59%。该出售的 SEC 备案提供了更多信息。在过去九十天内，内部人士出售了价值 $2,416,902 的 56,441 股公司股票。公司内部人士持有 15.90% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Vera Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Vera Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in VERA. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics during the fourth quarter valued at about $46,000. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics during the second quarter valued at about $51,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at about $71,000. Tower Research Capital LLC TRC increased its position in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock valued at $99,000 after buying an additional 2,757 shares during the period. Finally, Sandia Investment Management LP bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at about $127,000. 99.21% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了对 VERA 的持股。洛杉矶资本管理公司在第四季度购买了价值约 $46,000 的 Vera Therapeutics 新股份。Quantbot Technologies LP 在第二季度购买了价值约 $51,000 的 Vera Therapeutics 新股份。Aster Capital Management DIFC Ltd 在第四季度购买了价值约 $71,000 的 Vera Therapeutics 新股份。Tower Research Capital LLC TRC 在第二季度将其在 Vera Therapeutics 的持股增加了 192.9%。Tower Research Capital LLC TRC 现在拥有 4,186 股公司的股票，价值 $99,000，此前在该期间又购买了 2,757 股。最后，Sandia Investment Management LP 在第四季度购买了价值约 $127,000 的 Vera Therapeutics 新股份。99.21% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Vera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Vera Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.</p>
<div class="lb-trans"><p>Vera Therapeutics 是一家临床阶段的生物技术公司，专注于开发新型免疫疗法，利用身体自身的调节性 T 细胞治疗自身免疫和炎症性疾病。通过利用专有的蛋白质工程平台，公司设计了选择性针对 Treg 的细胞因子变体，旨在恢复免疫平衡并提供针对性的、改变疾病进程的效果。其产品管线包括多个针对慢性炎症和自身免疫特征的临床前和临床候选药物。</p>
</div><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p>
<div class="lb-trans"><p>Vera Therapeutics 成立于 2018 年，总部位于马萨诸塞州剑桥，与领先的学术和研究机构合作，推动其开发项目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.36 EPS

Market Beat

Vera Therapeutics

Invesco Nasdaq Biotechnology ETF

Vera Therapeutics（NASDAQ:VERA）公布季度财报，每股收益比预期低 0.36 美元